KYM-1Homo sapiens (Human)Cancer cell line
Also known as: KYM1, Kym-1
Quick Overview
Human rhabdomyosarcoma cell line for cancer research.
Detailed Summary
Research Applications
Key Characteristics
Basic Information
| Database ID | CVCL_3007 |
|---|---|
| Species | Homo sapiens (Human) |
| Tissue Source | Neck[UBERON:UBERON_0000974] |
Donor Information
| Age Category | Pediatric |
|---|---|
| Sex | Male |
| Race | asian |
Disease Information
| Disease | Embryonal rhabdomyosarcoma |
|---|---|
| Lineage | Soft Tissue |
| Subtype | Embryonal Rhabdomyosarcoma |
| OncoTree Code | ERMS |
DepMap Information
| Source Type | HSRRB |
|---|---|
| Source ID | ACH-000607_source |
Known Sequence Variations
| Type | Gene/Protein | Description | Zygosity | Note | Source |
|---|---|---|---|---|---|
| Gene deletion | SMARCB1 | - | Homozygous | - | PubMed=11921280 |
Haplotype Information (STR Profile)
Short Tandem Repeat (STR) profile for cell line authentication.
Loading gene expression data...
Publications
Pan-cancer proteomic map of 949 human cell lines.";
Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Cancer Cell 40:835-849.e8(2022).
Assessing alveolar rhabdomyosarcoma cell lines as tumor models by comparison of mRNA expression profiles.
Batchu S., Kellish A.S., Hakim A.A.
Gene 760:145025.1-145025.5(2020).
Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
Sellers W.R., Gygi S.P.
Cell 180:387-402.e16(2020).
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Sellers W.R.
Nature 569:503-508(2019).
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
Cancer Res. 79:1263-1273(2019).
A landscape of pharmacogenomic interactions in cancer.";
Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
Cell 166:740-754(2016).
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Loewer M., Sahin U., Castle J.C.
Genome Med. 7:118.1-118.7(2015).
Genome-wide approach to identify second gene targets for malignant rhabdoid tumors using high-density oligonucleotide microarrays.
Ogawa S.
Cancer Sci. 105:258-264(2014).
Cetuximab promotes anticancer drug toxicity in rhabdomyosarcomas with EGFR amplification in vitro.
Kitagawa Y., Morikawa Y., Kuroda T.
Oncol. Rep. 30:1081-1086(2013).
Proof-of-concept rare cancers in drug development: the case for rhabdomyosarcoma.
Sokolowski E., Turina C.B., Kikuchi K., Langenau D.M., Keller C.
Oncogene 33:1877-1889(2014).
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
Nature 483:603-607(2012).
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Haber D.A.
Cancer Res. 70:2158-2164(2010).
Identification of side population cells (stem-like cell population) in pediatric solid tumor cell lines.
Hayashi Y.
J. Pediatr. Surg. 42:2040-2045(2007).
Global gene expression profiling of PAX-FKHR fusion-positive alveolar and PAX-FKHR fusion-negative embryonal rhabdomyosarcomas.
Olshen A.B., Barr F.G., Ladanyi M.
J. Pathol. 212:143-151(2007).
Aberrations of the hSNF5/INI1 gene are restricted to malignant rhabdoid tumors or atypical teratoid/rhabdoid tumors in pediatric solid tumors.
Gilles F.H., Sugita K., Abe S., Sako M., Hashizume K., Hayashi Y.
Genes Chromosomes Cancer 34:33-41(2002).
Screening the p53 status of human cell lines using a yeast functional assay.
Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.
Mol. Carcinog. 19:243-253(1997).
Characterization of a human rhabdomyosarcoma cell strain in tissue culture.
Sekiguchi M., Shiroko Y., Suzuki T., Imada M., Miyahara M., Fujii G.
Biomed. Pharmacother. 39:372-380(1985).